Program
sunvozertinib
Also written as “DZD9008”, “Sunvozertinib” and “DZD9008+AZD4205”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lymphoma, B-Cell, led by Dizal Pharmaceuticals.
Furthest: phase 3, since Dec 20, 202212 company-led studies, 5 open or runningNext primary completion: Sep 2029 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dizal Pharmaceuticals | 125 open or running | phase 3since Dec 20, 2022 | May 21, 2019 | Sep 2029phase 3 · NCT07182682 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 21, 2019First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03974022 · 315 enrolled · United States, Argentina, Australia and more
- Oct 28, 2019Phase 2 study in Lymphoma, B-CellNCT04148742 · China
- May 13, 2021Phase 1 study in Healthy VolunteersNCT04909242 · 78 enrolled · United States
- Nov 22, 2021Phase 1 study in Healthy VolunteersNCT05159895 · 8 enrolled · United States
- May 28, 2022Phase 1 study in Healthy SubjectsNCT05418582 · 40 enrolled · United States
- Dec 20, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05668988 · 324 enrolled · United States, Argentina, Australia and more
- Jan 12, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05712902 · 104 enrolled · China
- Jun 22, 2023Phase 1 study in Carcinoma, Non-Small-Cell LungNCT05926180 · 25 enrolled · China
- Sep 6, 2023Phase 1 study in Hepatic ImpairmentNCT06084104 · 17 enrolled · United States
- Feb 7, 20242 phase 2 studies in Carcinoma, Non-Small-Cell LungNCT06295432, NCT06276283
- Sep 3, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07182682 · 360 planned · China
Ahead
- Sep 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07182682
TargetBeta
“An orally available, irreversible, dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) that shows similar activity against certain activating mutations, including exon 20 insertions (exon20ins), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sevabertinibrule | Bayer | phase 3 | 8 |
| enozertinibrule | oric-pharmaceuticals | phase 2 | 3 |
| EGFR/HER2 Mutant-selective Inhibitor BH-30643rule | blossomhill-therapeutics | phase 2 | 1 |
| GENSCI139rule | Changchun GeneScience Pharmaceutical | phase 1 | 1 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07182682Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Sep 2029 | 360 |
| NCT06295432Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Jun 8, 2026 | 30 |
| NCT06276283Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Dec 31, 2025 | 60 |
| NCT06084104Hepatic Impairment · United States | 1 | Completed | Jun 12, 2024 | 17 |
| NCT05926180Carcinoma, Non-Small-Cell Lung · China | 1 | Completed | May 16, 2024 | 25 |
| NCT05712902Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | Oct 17, 2022 | 104 |
| NCT05668988Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 16, 2026 | 324 |
| NCT05418582Healthy Subjects · United States | 1 | Completed | Jun 1, 2022 | 40 |
| NCT05159895Healthy Volunteers · United States | 1 | Completed | Mar 30, 2022 | 8 |
| NCT04909242Healthy Volunteers · United States | 1 | Completed | Feb 7, 2022 | 78 |
| NCT04148742Lymphoma, B-Cell · China | 2 | Withdrawn | Jul 2023 | 0 |
| NCT03974022Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 2 | Active, not recruiting | Jul 29, 2024 | 315 |
How it is read
Names in the registry
- “DZD9008”, 6 entries
- “sunvozertinib”, 2 entries
- “Sunvozertinib”, 2 entries
- “DZD9008+AZD4205”, 1 entry
- “DZD9008 plus Bevacizumab”, 1 entry
Codes read as this program: DZD9008.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.